Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Management Tracks

Wiggins, Simon join C-suite at Vaxcyte

Plus AZ’s Sheldon joining GSK (at last) and updates from Sudo, Walden, 1910 and more

October 12, 2022 12:22 AM UTC

Vaccine play Vaxcyte Inc. (NASDAQ:PCVX) bolstered its C-suite with the addition of Mark Wiggins as chief business officer (CBO) and Jakub Simon as CMO. Wiggins, a former EVP of business development at Biogen Idec Inc., was most recently CBO of Tracon Pharmaceuticals Inc. (NASDAQ:TCON). Simon, who has been consulting for Vaxcyte, was director of clinical research for vaccines at Merck & Co. Inc. (NYSE:MRK).

After battling it out in the courts, GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and AstraZeneca plc (LSE:AZN; NASDAQ:AZN) have reached an agreement for Chris Sheldon to join GSK, where he will become SVP of commercial portfolio, according to a GSK spokesperson. At AZ, Sheldon has held leadership roles for nearly two decades years. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article